HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has received a Paragraph IV Certification Notice from Apotex Inc. advising that it has filed an Abbreviated New Drug Application (ANDA) for generic versions of the three Zanaflex Capsules™ (tizanidine hydrochloride) dosage strengths. The Company is reviewing the Notice of Certification. Acorda continues to have full confidence in its intellectual property protecting Zanaflex Capsules™.
